Venture Partners Ii, Lp Sca... Net Worth

The estimated Net Worth of Venture Partners Ii, Lp Sca... is at least $142 Milhão dollars as of 21 September 2011. Venture Sca owns over 1,250,000 units of Zogenix Inc stock worth over $141,978,847 and over the last 13 years Venture sold ZGNX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Sca ZGNX stock SEC Form 4 insiders trading

Venture has made over 2 trades of the Zogenix Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently Venture bought 1,250,000 units of ZGNX stock worth $2,500,000 on 21 September 2011.

The largest trade Venture's ever made was buying 1,250,000 units of Zogenix Inc stock on 21 September 2011 worth over $2,500,000. On average, Venture trades about 782,973 units every 25 days since 2011. As of 21 September 2011 Venture still owns at least 5,321,546 units of Zogenix Inc stock.

You can see the complete history of Venture Sca stock trades at the bottom of the page.

Insiders trading at Zogenix Inc

Over the last 14 years, insiders at Zogenix Inc have traded over $5,100,850 worth of Zogenix Inc stock and bought 57,764,538 units worth $193,451,745 . The most active insiders traders include Advisors Llcperceptive Life..., Nicole Vitullo, eJesse I Treu. On average, Zogenix Inc executives and independent directors trade stock every 34 days with the average trade being worth of $13,059,406. The most recent stock trade was executed by Erle T Mast on 1 February 2022, trading 1,250 units of ZGNX stock currently worth $15,000.

What does Zogenix Inc do?

Zogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA® (fenfluramine) oral solution has been approved by the U.S. FDA and the European Medicines Agency and is in development in Japan for the treatment of seizures associated with Dravet syndrome, a rare, severe lifelong epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, another rare epilepsy, and one for MT1621, an investigational therapy for the treatment of a rare genetic disorder called TK2 deficiency. Zogenix is also collaborating with Tevard Biosciences to identify and develop potential next-generation gene therapies for Dravet syndrome and other genetic epilepsies.

Complete history of Venture Sca stock trades at Horizon Therapeutics Plc e Zogenix Inc

Zogenix Inc executives and stock owners

Zogenix Inc executives and other stock owners filed with the SEC include:

• Stephen Farr,
  President, Chief Executive Officer, Director
• Bradley Galer,
  Executive Vice President, Chief Medical Officer
• Michael Smith,
  Chief Financial Officer, Executive Vice President, Treasurer
• Gail Farfel,
  Executive Vice President, Chief Development Officer
• Ashish Sagrolikar,
  Executive Vice President, Chief Commercial Officer
• Dr. Stephen J. Farr,
  Co-Founder, CEO, Pres & Director
• Shawnte M. Mitchell,
  Exec. VP, Gen. Counsel & Sec.
• Dr. Bradley S. Galer,
  Exec. VP & Chief Medical Officer
• Dr. Gail M. Farfel,
  Exec. VP & Chief Devel. Officer
• Michael P. Smith,
  Exec. VP, CFO & Treasurer
• Ashish M. Sagrolikar,
  Exec. VP & COO
• Cam Garner,
  Independent Chairman of the Board
• Erle Mast,
  Independent Director
• Louis Bock,
  Independent Director
• Mark Wiggins,
  Independent Director
• James Breitmeyer,
  Independent Director
• Renee Tannenbaum,
  Independent Director
• Denelle Waynick,
  Independent Director
• Mary Stutts,
  Independent Director
• Caroline Loewy,
  Independent Director
• Shawnte Mitchell,
  Executive Vice President, General Counsel, Secretary
• Stephen H. Jenner,
  VP of Marketing
• Bret E. Megargel,
  VP of Corp. Devel.
• Melinda Baker,
  Sr. Director of Corp. Communications
• Jeff D. Durflinger,
  VP of Technical Operations & Product Supply
• Ann D Rhoads,
  EVP, CFO, Treasurer & Sec.
• Thierry J.P. Darcis,
  EVP / General Manager, Europe
• Venture Partners Ii, Lp Sca...,
  
• Growth Partners Ii L P Chic...,
  
• Advisors Llcperceptive Life...,
  
• Roger Hawley,
  Chief Executive Officer
• James C Blair,
  Director
• Richard Scott Shively,
  Chief Commercial Officer
• Nicole Vitullo,
  10% owner
• Ken Haas,
  Director
• Cynthia Y Robinson,
  Chief Development Officer
• Brian K Halak,
  10% owner
• Arda Phd Minocherhomjee,
  Director
• Kurt Wheeler,
  Director
• Kathleen K Schoemaker,
  10% owner
• Lifesciences I, L.P.Clarus ...,
  
• Parters Vii L P Domain,
  10% owner
• Vi Associates, L.P. Dp,
  10% owner
• Venture Partners Ii, Lp Sca...,
  
• Brian H Dovey,
  10% owner
• Partners Vi, L.P. Domain,
  10% owner
• Jesse I Treu,
  10% owner
• Mcnerney & Partners Lp Thom...,
  
• Vii Associates Lp Dp,
  10% owner
• Lifesciences I, L.P.Clarus ...,